Medicaid Outcomes-Based Payment Model For Cell, Gene Therapy to Launch In 2025

But CMMI does not yet have a launch date for the proposed Medicare demonstration on drugs cleared through FDA’s accelerated approval pathway and the demonstration allowing Part D plans to offer certain high-value generics with a $2 beneficiary copay.